In a phase III trial of patients with progressive radioiodine-refractory differentiated thyroid cancer, lenvatinib significantly extended progression-free survival compared to placebo.
A phase III trial demonstrated a 37 percent improvement in progression-free survival when using the investigational compound LBH589 (panobinostat) in combination with bortezomib and dexamethasone compared to treatment with the same regimen with placebo in patients with relapsed or relapsed and refractory multiple myeloma.
Data from the phase III RESONATE trial showed that monotherapy ibrutinib significantly lengthened progression-free survival and overall survival compared to ofatumumab in relapsed or refractory chronic lymphocytic leukemia or small lymphocytic leukemia.
By priming pancreatic ductal adenocarcinomas with a therapeutic vaccine and a low-dose chemotherapy combination prior to surgery, researchers converted PDACs into cancers that may respond to immunotherapy.
A drug used to treat men with late-stage prostate cancer proved effective in stemming progression of the disease in research participants who had not yet received chemotherapy and extended their survival, according to results from a multi-national phase III clinical trial
New overall survival data of two phase III clinical trials, LUX-Lung 3 and LUX-Lung 6, demonstrated that patients with advanced non-small cell lung cancer whose tumors have the most common epidermal growth factor receptor mutation lived longer if treated with first-line afatinib compared to chemotherapy.
FDA granted orphan drug designation to ADXS-HPV for the treatment of stage II-IV invasive cervical cancer.
The National Cancer Institute Cancer Therapy Evaluation Program approved the following clinical research studies last month. For further information, contact the principal investigator listed.
A phase III trial of rolapitant, an investigational neurokinin-1 receptor antagonist in development for the prevention of chemotherapy-induced nausea and vomiting, was successful in achieving statistical significance for its primary and all secondary endpoints.
In a phase I study, tumors shrank or disappeared and disease progression was temporarily halted in 15 children with advanced neuroblastoma enrolled in a safety study of an experimental antibody produced at St. Jude Children's Research Hospital.
